Sign in

CIK 0001664710

  • Non-accelerated filer
  • Smaller reporting company

Keros Therapeutics, Inc.

Sign in to watch
Ticker
KROS
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Entity type
Operating
EIN
811173868
Phone
+1 617-314-6297
Business address
1050 WALTHAM STREET, SUITE 302, LEXINGTON, MA, 02421
  1. 4 Derivatives Options or other derivatives
  2. 4 Open-market buy 10% owner bought 120,000 shares at $16.00 ($1,920,000)
  3. 4 Open-market buy Chief Executive Officer bought 20,000 shares at $16.00 ($320,000)
  4. 4 Open-market buy 10% owner bought 437,499 shares at $16.00 ($6,999,984)
  5. 4 Open-market buy Director bought 375,200 shares at $16.00 ($6,003,200)
  6. 4 Open-market buy Director bought 437,499 shares at $16.00 ($6,999,984)
  7. 4 Open-market buy Director bought 120,000 shares at $16.00 ($1,920,000)
  8. 4 Conversion Director acquired 915,725 shares (conversion)
  9. 4 Open-market buy Director bought 437,499 shares at $16.00 ($6,999,984)
  10. 4 Open-market buy Director bought 375,200 shares at $16.00 ($6,003,200)
  11. 4 Derivatives Options or other derivatives
  12. 4 Derivatives Options or other derivatives
  13. 4 Derivatives Options or other derivatives
  14. 4 Derivatives Options or other derivatives
  15. 3 Insider Initial Statement of Ownership
  16. 3 Insider Initial Statement of Ownership
  17. 3 Insider Initial Statement of Ownership
  18. 3 Insider Initial Statement of Ownership
  19. 3 Insider Initial Statement of Ownership
  20. 3 Insider Initial Statement of Ownership

Page 10 of 11 · 207 filings